Some things will remain the same for Vertex five years from now, including its dominance in treating cystic fibrosis (CF). However, the company will likely achieve success in several new markets ...

Global tax technology company Vertex Inc. has appointed Ralf Gärtner as senior vice president and regional manager for Europe, reinforcing its commitment to innovation and compliance across the region ...

During Vertex’s third-quarter presentation, Chief Commercial Officer Duncan McKechnie cited several numbers that suggest the launch of its long-awaited, non-opioid pain reliever Journavx is trending ...

Vertex, Inc. (NASDAQ:VERX) announced on Tuesday that president and CEO David DeStefano will step down from his roles effective November 10, 2025. Following an extensive search assisted by an ...

TÜV Rheinland assessed modules across five dimensions, including thermal cycling, mechanical load and dynamic stress, UV exposure and humidity-freeze, damp heat and PID, the Vertex N Shield module ...

With the business potentially at an important milestone, we thought we'd take a closer look at Vertex, Inc.'s (NASDAQ:VERX) future prospects. Vertex, Inc., together with its subsidiaries, provides ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

Despite the clinical setback, Vertex delivered a solid Q2 performance. The company reaffirmed its full-year revenue guidance, which gave investors a bit of reassurance. However, the market reaction ...

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...

A Hyperbola-1 solid rocket lifts off from Jiuquan spaceport, July 29, 2025, carrying the HS-9 software-defined remote sensing satellite into orbit. Credit: iSpace HELSINKI — Chinese launch startup ...

Boston and London biotech company Vertex Pharmaceuticals is on a roll. In the past year and a half, Vertex worked with CRISPR Therapeutics to develop the first CRISPR treatment approved by the U.S.